Comparing of Global Blood Therapeutics Inc. (GBT) and Axovant Sciences Ltd. (NASDAQ:AXON)

We will be comparing the differences between Global Blood Therapeutics Inc. (NASDAQ:GBT) and Axovant Sciences Ltd. (NASDAQ:AXON) as far as profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Blood Therapeutics Inc. N/A 0.00 166.24M -3.42 0.00
Axovant Sciences Ltd. N/A 0.00 145.34M -1.53 0.00

Demonstrates Global Blood Therapeutics Inc. and Axovant Sciences Ltd. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us Global Blood Therapeutics Inc. and Axovant Sciences Ltd.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Global Blood Therapeutics Inc. 0.00% -36.2% -33.6%
Axovant Sciences Ltd. 0.00% -302.2% -119.2%

Risk and Volatility

Global Blood Therapeutics Inc. is 210.00% more volatile than Standard and Poor’s 500 due to its 3.1 beta. Axovant Sciences Ltd.’s 0.37 beta is the reason why it is 63.00% less volatile than Standard and Poor’s 500.

Liquidity

Global Blood Therapeutics Inc.’s Current Ratio and Quick Ratio are 14.6 and 14.6 respectively. The Current Ratio and Quick Ratio of its competitor Axovant Sciences Ltd. are 2 and 2 respectively. Global Blood Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Axovant Sciences Ltd.

Insider & Institutional Ownership

The shares of both Global Blood Therapeutics Inc. and Axovant Sciences Ltd. are owned by institutional investors at 14.72% and 9.2% respectively. 4.6% are Global Blood Therapeutics Inc.’s share owned by insiders. Comparatively, insiders own roughly 61.44% of Axovant Sciences Ltd.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Global Blood Therapeutics Inc. 37.54% 4.05% -4.87% -5.28% -1.07% 10.24%
Axovant Sciences Ltd. -31.49% -39.51% -40.95% -75.25% -75.3% -76.47%

For the past year Global Blood Therapeutics Inc. had bullish trend while Axovant Sciences Ltd. had bearish trend.

Summary

Global Blood Therapeutics Inc. beats Axovant Sciences Ltd. on 4 of the 6 factors.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of AlzheimerÂ’s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.